Sage Therapeutics and Biogen Announce Positive Pivotal Phase 3 Results for Zuranolone, an Investigational Two-Week, Once-Daily Therapeutic Being Evaluated for Major Depressive Disorder

Sage Therapeutics

Clinical Results

VistaGen Reports Topline Phase 2 Results for AV-101 as an Adjunctive Treatment of Major Depressive Disorder

VistaGen Therapeutics

Drug Development

NeuroRx Reports Phase 2 Efficacy for NRX-101, a Breakthrough Therapy Targeting Suicidal Bipolar Depression

NeuroRx

FDA Approval

FDA Approves New Nasal Spray Medication for Treatment-resistant Depression; Available Only at a Certified Doctor's Office or Clinic

U.S. Food & Drug Administration

FDA

FDA Advisory Committee Recommends Approval of SPRAVATO™ (esketamine) Nasal Spray CIII for Adults with Treatment-Resistant Depression

Janssen Pharmaceutical Companies

Depression

New Data Presented at Psych Congress 2018 Sheds Light on the Significant Economic Burden of Treatment-Resistant Depression Amongst U.S. Veterans

Janssen Pharmaceutical Companies

Innovation

Shining a Light on Depression - How Infrared Light Can Treat Depression

The Neuro-Laser Foundation

Data Presentation

Janssen to Present Data in Treatment-Resistant Mental Ilnesses

Janssen Pharmaceutical Companies